.Focus on: HIV/AIDS

HIV/AIDS remains one of the world’s greatest public health challenges, particularly in low-and middle income counties (LMICs). Building upon significant achievements of the Sustainable Development Goals (SDGs) in reducing the mortality from and incidences of HIV/AIDS, IFPMA member companies and associations endorse the UN 2030 Agenda for Sustainable Development and the global commitment to accelerate the fight against AIDS, ending the epidemic by 2030. 

The research-based pharmaceutical industry is actively engaged in a number of initiatives to improve screening, timely diagnosis and access to treatment for HIV, awareness raising and education to halt transmission and reduce stigma, and research and development of new medicines and vaccines to combat this disease.

Our industry is currently developing 52 medicines and vaccines for HIV infection (ref: PhRMA), focusing on additional combination treatments, more effective therapies, and preventative vaccines. These medicines and vaccines are either in clinical trials or awaiting review. The 52 medicines and vaccines in the development pipeline include:

  • 32 antiretrovirals and antivirals, 16 vaccines and 4 cell therapies
  • A first-in-class medicine intended to prevent HIV from breaking through the cell membrane.

Global efforts to battle this pandemic are making a significant difference; still, AIDS remains a leading cause of death in LMICs. Global efforts to battle this pandemic are making a significant difference; still, AIDS remains a leading cause of death in LMICs. Copyright ViiV Healthcare, SOTENI Kenya

HIV/AIDS today

Global efforts to battle this pandemic are making a significant difference; still, AIDS remains a leading cause of death in LMICs. In 2016, 1 million people died from AIDS-related illness. 

According to the United Nations Aids Agency (UNAIDS), by June 2017, 20.9 million people were receiving antiretroviral therapy (ART) worldwide. As a result of recent advances in access to antiretroviral drugs (ARVs), HIV-positive people now live longer and healthier lives. In 2016, around 1.8 million people were newly infected with HIV, a 39% decrease from the 3 million at the peak of the epidemic in the late 1990s. In sub-Saharan Africa, new HIV infections have fallen by 48% since 2000.

However, HIV infections are rising at a rapid pace in countries that have not expanded health and HIV services. In Eastern Europe and Central Asia, infections have risen by 60% since 2010 and AIDS-related deaths by 27%. 

HIV/AIDS presents social as well as medical challenges, when looking to ensure everyone who needs treatment will come forward and properly adhere to ART. Guaranteeing the changes in behavior that can protect people from infection requires continued political commitment and the contribution of stakeholders from a range of different sectors.

Doing our part – partnerships that accelerate the fight against AIDS

Programs to scale up HIV prevention, treatment, and care, as well as to provide support to the communities and loved ones of people living with HIV, are necessary to achieve the vision of a world without AIDS. IFPMA member companies and associations support a variety of initiatives to halt the global HIV/AIDS epidemic.

Education and awareness raising to prevent transmission of HIV and reduce stigma against people living with the disease include partnerships such as ViiV Healthcare’s Positive Action, with grassroots action to empower people living with HIV/AIDS, as well as BMS’ Secure the Future, funding projects in sub-Saharan Africa to end transmission of this disease.

In cooperation with generics manufacturers or groups such as Medicines Patent Pool, IFPMA companies including AbbVie, BMS, GSK, Janssen, MSD*, Pfizer, Roche, and Shionogi have licensing agreements for expanded access to treatment in low-income countries. Other partnerships to increase access to care for people with AIDS and others impacted by the disease include AmpliCare, for early diagnosis of babies at risk of HIV, and MSD’s C-MAP, to support the Chinese National HIV/AIDS Prevention and Control Action Plan.

Alongside education and access to care, the research and development of new treatments and vaccines will provide long-term solutions to halt the global AIDS epidemic. This is why the researched-based pharmaceutical industry is also actively involved research partnerships with governments, NGOs and academia, such as the International AIDS Vaccine Initiative (IAVI), International Partnership for Microbicides (IPM), and HIVACAT: HIV Vaccine Development.

We invite you to learn more about these programs and many others by following the link “HIV/AIDS” under Partnership Information to the right.

Join us in raising awareness around HIV/AIDS using the hashtags #healthpartnerships, #HIV, and #WAD2017 on social media.

*MSD (Merck Sharp and Dohme) is known as Merck & Co., Inc. in the U.S. and Canada.

 

More information can be found here:

UNAIDS - 2017 Report: Right to Health (PDF)

PhRMA - 2014 Report: Medicines in Development for HIV/AIDS (PDF)

Assessing the Value of Biopharmaceutical Innovation in Key Therapy Areas in MICs AIDS section (pdf)

Evidence on Access to Essential Medicines for the Treatment of HIV/AIDS (pdf)

The Power of Sustainable and Transformational Health Partnerships (infographic)

World AIDS Day: On the Fast Track to end AIDS (UNAIDS)

Licenses of the Medicines Patent Pool (MPP)

Getting to Zero: end AIDS by 2030 (WHO)

Partnership information

Therapeutic Focus Infectious Diseases

Disease(s) HIV/AIDS

Region(s) East Asia & Pacific, Europe & Central Asia, Latin America & Caribbean, Middle East & North Africa, North America, South Asia, Sub-Saharan Africa

Number of Countries 198

Country(ies) Afghanistan, Albania, Algeria, Andorra, Angola, Antigua and Barbuda, Argentina, Armenia, Australia, Austria, Azerbaijan, Bahamas, Bahrain, Bangladesh, Barbados, Belarus, Belgium, Belize, Benin, Bhutan, Bolivia, Bosnia and Herzegovina, Botswana, Brazil, Brunei, Bulgaria, Burkina Faso, Burundi, Cambodia, Cameroon, Canada, Cape Verde, Central African Republic, Chad, Chile, China, Colombia, Comoros, Congo, Cook Islands, Costa Rica, Côte d'Ivoire, Croatia, Cuba, Cyprus, Czech Republic, Democratic Republic of the Congo, Denmark, Djibouti, Dominica, Dominican Republic, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Estonia, Ethiopia, Fiji, Finland, France, French Guiana, Gabon, Georgia, Germany, Ghana, Greece, Grenada, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Honduras, Hong-Kong, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kiribati, Kosovo, Kuwait, Kyrgyzstan, Lao PDR, Latvia, Lebanon, Lesotho, Liberia, Libya, Liechtenstein, Lithuania, Luxembourg, Macedonia, Madagascar, Malawi, Malaysia, Maldives, Mali, Malta, Marshall Islands, Mauritania, Mauritius, Mexico, Micronesia, Moldova, Mongolia, Montenegro, Morocco, Mozambique, Myanmar, Namibia, Nauru, Nepal, Netherlands, New Zealand, Nicaragua, Niger, Nigeria, Niue, North Korea, Norway, Oman, Pakistan, Palau, Panama, Papua New Guinea, Paraguay, Peru, Philippines, Poland, Portugal, Qatar, Romania, Russia, Rwanda, Samoa, Sao Tome and Principe, Saudi Arabia, Senegal, Serbia, Seychelles, Sierra Leone, Singapore, Slovakia, Slovenia, Solomon Islands, Somalia, South Africa, South Korea, South Sudan, Spain, Sri Lanka, St. Kitts and Nevis, St. Lucia, St. Vincent and the Grenadines, Sudan, Suriname, Swaziland, Sweden, Switzerland, Syria, Taiwan, Tajikistan, Tanzania, Thailand, The Gambia, Timor-Leste, Togo, Tonga, Trinidad and Tobago, Tunisia, Turkey, Turkmenistan, Tuvalu, Uganda, Ukraine, United Arab Emirates, United Kingdom, United States of America, Uruguay, Uzbekistan, Vanuatu, Venezuela, Vietnam, West Bank and Gaza, Yemen, Zambia, Zimbabwe

Start Date 2000

Anticipated completion date Ongoing